Candidalysin IgG

Most healthy people carry Candida yeast on their skin and in their gut and never notice it. The question that matters, when someone falls ill, is whether that same yeast has pushed into the blood or deep tissue. That shift, from harmless resident to invasive infection, is one of the harder calls in medicine, and it changes how the illness is treated.

When Candida grows hyphae, its thread-like form, some species release a toxin called candidalysin. The toxin can punch holes in human cells and trigger inflammation. Your immune system can answer by making antibodies against it, and this test measures one of those antibodies in your blood.

What This Antibody Reflects

The full name is anti-candidalysin IgG. IgG is a long-lasting antibody class. The lab measures it in serum. Serum is the liquid part of blood after clotting.

Candidalysin is a short toxin made during filament growth, especially when Candida is damaging a surface or invading tissue. The test does not measure the toxin itself. It measures how much of your own antibody against the toxin is circulating, which shows that your immune system has run into it.

One catch shapes everything. Candidalysin has been found in Candida albicans, Candida dubliniensis, and Candida tropicalis. Other important Candida species, including Candida glabrata, Candida parapsilosis, and Candida auris, do not appear to carry the same candidalysin system. A serious infection from one of those species can leave this antibody low.

Telling Invasion From Colonization

This is the job the antibody is being tested for. So far, the human diagnostic evidence is one pediatric study. In that study, blood from children with proven or probable invasive candidiasis was compared with children without it.

Source: Luo et al., 2025, a single pediatric cohort.

In plain terms, the antibody caught most real infections and cleared most people who did not have one, but it was far from perfect. It ran positive in more than 80 out of 100 children with Candida albicans or Candida tropicalis cultured from blood, stool, urine, or sputum. A stool, urine, or sputum culture does not prove invasion by itself; in the study, those cases were counted only when risk factors and clinical signs also fit.

For you, that means a high result is worth taking seriously as a prompt to look harder, not as a verdict. It earns its place next to a culture and the clinical picture, not instead of them.

Where Blood Culture and Beta-D-Glucan Fall Short

Blood culture is the standard test for Candida in the bloodstream, and a positive result matters. The problem is that it catches somewhere between 21 and 71 out of 100 true cases, takes two to five days, and often misses infection walled off in deep tissue. A common backup, the beta-D-glucan test, picks up a sugar found in many fungi, so it is broad but easily thrown off by things like surgical gauze, albumin infusions, and dialysis.

Against that backdrop, the antibody adds a different kind of evidence: a species-limited record that your immune system met the Candida toxin. It agreed only moderately with fungal culture and barely at all with beta-D-glucan. That means the three tests look at different things. Culture confirms a live organism, beta-D-glucan screens broadly across fungi, and this antibody points at the immune response to one Candida toxin family.

Why a High Number Is Not Proof

Some healthy children in the study had antibody levels as high as the sick ones. That is not a measurement error. Colonizing Candida can grow filaments in the gut and make small amounts of the toxin, so your immune system can build antibodies to it without invasive disease. This is an exposure marker, not an infection switch. A high number tells you the toxin has been around; whether it reflects invasion depends on your symptoms, your cultures, and how well your immune system is working.

What the Level Tracked With

Within that same small study, the combined IgG-plus-IgM signal moved with a few site-specific signals. In children with Candida in the blood, higher antibody went with higher monocyte-related counts. In children with Candida in stool, it tracked with liver enzyme patterns. In children with Candida in sputum, it tracked with eosinophils, white cells often tied to allergy-type inflammation. These are early correlations from one cohort, not settled rules.

The Toxin's Wider Role

Candidalysin itself has drawn attention beyond bloodstream infection. That is the toxin, not the antibody. In people with inflammatory bowel disease, Candida albicans strains with higher immune-cell-damaging capacity aggravated gut inflammation through candidalysin-dependent pathways. In severe COVID-19, broader Candida albicans IgG responses marked gut fungal overgrowth and longer immune activation. Those findings are background on why candidalysin matters. They are not evidence that this specific antibody test diagnoses those conditions.

Why One Reading Has Limits

A single antibody level is a snapshot, and this one has real blur built in. The pediatric study drew serum within two weeks of a positive culture and did not follow people over time, so no one has mapped when this antibody first appears, when it peaks, or how long it lingers. IgG antibodies can outlast the trigger. On its own, this test cannot tell an active infection from one you have already cleared.

That limits retesting. Repeating the test can help when a result does not fit the rest of the picture or when a lab error is possible, but serial trends are not validated for this marker. There is no standardized cutoff yet. Your result should be read against the lab method and the whole clinical picture, not against a universal range.

When Results Can Be Misleading

A few things can push this test in the wrong direction:

• Colonization, not invasion: Candida in the gut can make enough toxin to raise the antibody, so a high number can appear without invasive disease.
• The wrong Candida species: the test is aimed at candidalysin-producing species, so infection from another Candida species can read falsely low.
• A weakened immune system: chemotherapy, immune-suppressing drugs, or impaired antibody production can blunt the response, though low total globulin did not always lower the result in the pediatric cohort.
• Treatment timing: antifungal treatment may reduce the infection before IgG falls, so a lingering antibody cannot prove current disease.
• Interfering antibodies: stray antibodies in the blood can distort immunoassay readings. A lab can sometimes check this with serial dilution or another interference check.

What to Do With an Out-of-Pattern Result

If the antibody comes back high and you are seriously ill, immunosuppressed, or have a positive culture, treat it as a reason to complete the workup. Pair it with fungal culture, beta-D-glucan, and where available Candida mannan antigen or Candida PCR. If bloodstream infection is possible, repeat blood cultures and species identification matter more than this antibody by itself.

Combinations are what matter. A positive antibody plus a positive sterile-site culture plus signs of infection is a pattern worth acting on quickly, with an infectious disease clinician involved because treatment means prescription antifungal therapy and source control decisions. A high antibody with no symptoms and no positive culture may reflect colonization or past exposure. Every accuracy number here comes from children, so how the test behaves in adults is still unknown. What adult data exist for other anti-Candida antibody assays are not encouraging: in a recent ICU sepsis study, antibody levels rose more with harmless colonization than with true invasive infection and lagged behind antigen-based tests, so this approach may translate poorly to adults.